Literature DB >> 7607278

Inherited resistance to activated protein C in a boy with multiple thromboses in early infancy.

W Zenz1, W Muntean, S Gallistl, B Leschnik, A Beitzke.   

Abstract

Resistance to activated protein C is a recently discovered genetic defect with a high prevalence in adult patients with thromboembolic disease. It is an autosomal dominant disorder and is ten times more common in these patients than antithrombin III-, protein C- and protein S deficiency together. In spite of this high prevalence among adults with thromboembolic disease no clinical manifestation in infancy so far has been reported. We describe a 4-year-old boy with a complex cardiac malformation and inherited resistance to activated protein C, who developed multiple thromboses after cardiac catheterization in early infancy. Conclusion. Resistance to activated protein C can cause thrombosis in infants and children if additional risk factors for the development of thrombosis are present.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7607278     DOI: 10.1007/BF01957363

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  12 in total

1.  Homozygous protein S deficiency in an infant with purpura fulminans.

Authors:  C Mahasandana; V Suvatte; A Chuansumrit; R A Marlar; M J Manco-Johnson; L J Jacobson; W E Hathaway
Journal:  J Pediatr       Date:  1990-11       Impact factor: 4.406

Review 2.  Hereditary protein C deficiency: a review of the genetics, clinical presentation, diagnosis and treatment.

Authors:  R A Marlar; S Mastovich
Journal:  Blood Coagul Fibrinolysis       Date:  1990-08       Impact factor: 1.276

3.  Resistance to activated protein C in nine thrombophilic families: interference in a protein S functional assay.

Authors:  E M Faioni; F Franchi; D Asti; E Sacchi; F Bernardi; P M Mannucci
Journal:  Thromb Haemost       Date:  1993-12-20       Impact factor: 5.249

4.  Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V.

Authors:  B Dahlbäck; B Hildebrand
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

5.  Alpha-2-macroglobulin may provide protection from thromboembolic events in antithrombin III-deficient children.

Authors:  L Mitchell; F Piovella; F Ofosu; M Andrew
Journal:  Blood       Date:  1991-11-01       Impact factor: 22.113

6.  Resistance to activated protein C as a basis for venous thrombosis.

Authors:  P J Svensson; B Dahlbäck
Journal:  N Engl J Med       Date:  1994-02-24       Impact factor: 91.245

7.  Anticoagulant protein C pathway defective in majority of thrombophilic patients.

Authors:  J H Griffin; B Evatt; C Wideman; J A Fernández
Journal:  Blood       Date:  1993-10-01       Impact factor: 22.113

8.  Tissue plasminogen activator (alteplase) treatment for femoral artery thrombosis after cardiac catheterisation in infants and children.

Authors:  W Zenz; W Muntean; A Beitzke; G Zobel; M Riccabona; A Gamillscheg
Journal:  Br Heart J       Date:  1993-10

9.  Protein S deficiency: early presentation and pulmonary hypertension.

Authors:  J O'Sullivan; R Chatuverdi; M K Bennett; S Hunter
Journal:  Arch Dis Child       Date:  1992-07       Impact factor: 3.791

10.  Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study.

Authors:  T Koster; F R Rosendaal; H de Ronde; E Briët; J P Vandenbroucke; R M Bertina
Journal:  Lancet       Date:  1993 Dec 18-25       Impact factor: 79.321

View more
  2 in total

Review 1.  Inherited defects of the protein C anticoagulant system in childhood thrombo-embolism.

Authors:  U Nowak-Göttl; K Auberger; U Göbel; W Kreuz; R Schneppenheim; H Vielhaber; W Zenz; B Zieger
Journal:  Eur J Pediatr       Date:  1996-11       Impact factor: 3.183

2.  Prevalence of factor V Leiden in children with thrombo-embolism.

Authors:  I Aschka; V Aumann; F Bergmann; U Budde; W Eberl; S Eckhof-Donovan; S Krey; U Nowak-Göttl; R Schobess; A H Sutor; J Wendisch; R Schneppenheim
Journal:  Eur J Pediatr       Date:  1996-12       Impact factor: 3.183

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.